
[…]
[…]
[…]
[…]
While most observational studies have not demonstrated an increase in malignancy independently associated with TNF inhibitor use, a meta-analysis of short-term clinical trials data suggested an increase in malignancy risk occurring within months of initiating therapy with monoclonal antibodies directed against TNF-α (infliximab and adalimumab).